Imatinib reduces blood-brain barrier permeability in a transient occlusion-reperfusion rodent model: A DCE-MRI study
Zamir Merali 1 , Jackie Leung 1 , and Andrea Kassner 1,2
Physiology and Experimental Medicine, The
Hospital for Sick Children, Toronto, Ontario, Canada,
Imaging, University of Toronto, Toronto, Ontario, Canada
The platelet-derived growth factor inhibitor, Imatinib,
has been shown to reduce blood-brain barrier (BBB)
permeability in a variety of neurologic conditions.
However, the clinical utility of this type of treatment
for ischemic stroke is still uncertain. We proposed to
use structural and DCE-MRI to quantify the BBB
stabilizing effect of Imatinib in a rodent stroke model.
Male Sprague-Dawley rats (n=25) underwent MCA
occlusion-perfusion surgery and was imaged at 5 and 24
hours. Treatment group rats received Imatinib while
controls received an equivalent volume of saline. At
24-hours, the Imatinib group had reduced infarct size
and permeability compared to controls.
This abstract and the presentation materials are available to members only;
a login is required.